WFH Released New Evidence-Based Guidelines on AAV Gene Therapy for Hemophilia
World Federation of Hemophilia shared on LinkedIn:
”The WFH has released new evidence-based guidelines on AAV gene therapy for hemophilia, covering eligibility, center readiness, infusion safety, and long-term monitoring.
A major step forward for people with bleedingdisorders.
Find out more”
The World Federation of Hemophilia (WFH) has released a new evidence-based clinical practice guideline focused on adeno-associated virus (AAV) gene therapy for people with hemophilia (PwH).
This marks the addition of a dedicated gene therapy section within the broader WFH Guidelines for the Management of Hemophilia.
The guideline offers practical, up-to-date recommendations to support clinicians and patients in navigating this rapidly advancing treatment landscape.
It aims to promote safe, informed, and equitable use of gene therapy across the global bleeding disorders community.
Stay updated with Hemostasis Today.
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25
-
Jan 7, 2026, 05:04Heghine Khachatryan on VWD: A Landmark in the History of Hematology
-
Jan 6, 2026, 13:39JAMA Neurology: No Added Benefit of Dual Therapy After Ischemic Stroke in Case of AFib
-
Jan 6, 2026, 10:10This is Fantastic: Shirley D’Sa on Transfusion-Free Christmas Milestone for 𝛃-Thalassaemia Patient at UCLH
-
Jan 6, 2026, 09:53Hamideh Yadegari: Coagulation–Inflammation Crosstalk: Mechanisms, Pathways, and Clinical Implications